Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 15;2(1):vdaa119. doi: 10.1093/noajnl/vdaa119

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 5. — Biospecimen and imaging of lesion #7, untreated glioblastoma. (A) PARPi-FL uptake blocking demonstrates the specificity of the compound. Biospecimen stained with the fluorescent version (PARPi-FL, top row) and blocked (co-incubated with a 100-fold excess of olaparib, bottom row). (B) Quantification of nuclear accumulation of PARPi-FL showed median fluorescence significantly higher (P < .001) than in the blocked tissue. (C) Axial [¹⁸F]PARPi uptake map, contrast T1-weighted image, and [¹⁸F]PARPi map overlaid on contrast T1-weighted image show untreated enhancing cancer in the temporal lobe with high [¹⁸F]PARPi uptake (arrow).